Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
